Pharmaceutical excipients are considered an essential part of modern drug formulation. Comprising approximately 50–90% of the finished product, excipients ensure that limitations of the API, such as poor solubility or stability, can be overcome, enabling effective performance and delivery in the end user...

Generic and biosimilar drugs are vitally important for healthcare systems around the world and are increasingly in demand from patients thanks to their affordability when compared with the branded originators...

As the modern drug development pipeline becomes ever more saturated with complex molecules and targets shift toward ‘undruggable’ protein–protein interfaces, formulators are facing a solubility crisis that traditional formulation approaches can no longer solve...

Sustainability has become a paramount consideration for global industries seeking to find a balance between meeting the needs of the current population without compromising future generations...

With an increasing proportion of niche therapies entering the development pipeline, the bio/pharma industry is having to pivot to more agile processes that work for smaller batch sizes..

As industry sharpens its focus on personalized medicine and orphan drugs, manufacturers are being required to adapt to the new process requirements of these more niche drugs...

For many years, the bio/pharma supply chain was operated primarily around cost optimization, which resulted in consolidation of API and raw material sourcing into a handful of global hubs...

For decades, the bio/pharmaceutical industry operated with a scale-up philosophy, which led to companies building increasingly massive facilities, housing large-volume stainless-steel bioreactors, to meet global demand for biologics...

Advanced therapy medicinal products (ATMPs) are groundbreaking, innovative treatments for many patients once considered untreatable...

Since the first DCAT Annual Dinner, which was held in 1926, New York City has played host to the multifaceted global event, DCAT Week...

Thanks to the foundational work of the Human Genome Project, which was completed over two decades ago in 2003, biopharmaceutical research and development has made great strides forward...

Traditional blockbuster therapies — high-volume, broad-scope drugs — are being rapidly superseded by high-precision, niche therapeutic platforms that target specific genetic pathways...

Traditionally, randomized controlled trials (RCTs) have been thought of as the gold standard when it comes to demonstrating the efficacy of an investigational drug product...

The clinical trial sector is currently experiencing an evolution thanks to various technological and approach innovations that is equivalent to the transition from paper to Electronic Data Capture (EDC) two decades ago...

The margin for error within drug development is becoming ever narrower, as R&D costs continue to rise, competition pressures intensify, and regulatory expectations grow…

Antibody-based therapeutics have revolutionized modern medicine through their remarkable specificity and efficacy in targeting cancer, autoimmune, and infectious diseases. More than 100 monoclonal antibodies (mAbs) have gained global clinical approval, reflecting their immense therapeutic demand...

Now that the latest J.P. Morgan Healthcare Conference has closed its doors and the dust has started to settle on the discussions and sentiments realized from event, the global bio/pharma industry is optimistic for M&A momentum in 2026...

Geopolitical challenges were on the ordre du jour for many industries in 2025, of particular concern were the U.S.-imposed tariffs, which shook global economies…

“We are definitely seeing that formulations and APIs are becoming more complex and this does present unique challenges for primary packaging,” notes Dr. Robert Lindner, Global Product Manager for Bulk and Sterile Cartridges at SCHOTT Pharma...

Currently, the bio/pharma investment landscape is quite different from what it was less than a decade ago, notes Julien Meissonnier, Independent Director on the Board for Prolific Machines and former Chief Scientific Officer for Catalent…